Regulatory Guidance Monthly Review - July 2022
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...
Regulatory Guidance Monthly Review - June 2022
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...
On-Demand Webinar: Natural History Study for Ultra-Rare Diseases
Were you able to join Veristat’s live webinar- “Strategies for Solving the Challenges of an...
Regulatory Guidance Monthly Review - May 2022
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...
Joining HIPRA to Take Aim at the Continuing Challenges of COVID-19
UPDATE – Veristat study collaboration with HIPRA leads to EMA approval of BIMERVAX® COVID-19 vaccine
The New EU Framework for In Vitro Diagnostics Enters into Application
The In Vitro Diagnostics Regulation (IVDR, EU 2017/746) enters into application in the European...
A Paradigm Shift in Monitoring Clinical Trials
What we know as work has experienced a major transformation. This shift and the changes it...
Regulatory Guidance Monthly Review - April 2022
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance...
Is it Possible to Gain Regulatory Approval Following a Single-Arm Study?
In this case study example - yes.
Veristat developed a thorough regulatory submission strategy and...